Dysregulated Phosphate Metabolism, Periodontal Disease, and Cancer: Possible Global Health Implications by Brown, Ronald B.
dentistry journal
Perspective
Dysregulated Phosphate Metabolism, Periodontal
Disease, and Cancer: Possible Global
Health Implications
Ronald B. Brown
School of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L 3G1, Canada;
r26brown@uwaterloo.ca; Tel.: +1-519-578-2094
Received: 31 December 2018; Accepted: 6 February 2019; Published: 11 February 2019


Abstract: An association between periodontal disease and cancer has been established in recent
studies, but no common etiology has been identified in the hopes of reducing the global burden
of these non-communicable diseases. This perspective article hypothesizes that the determinant
mediating the association of periodontal disease with cancer is dysregulated phosphate metabolism.
Phosphate, an essential dietary micronutrient, is dysregulated in chronic kidney disease, and both
cancer and periodontal disease are associated with chronic kidney disease. Reviewed evidence
includes the association between phosphate toxicity and cancer development, and the association
between periodontal disease and chronic kidney disease-mineral and bone disorder includes
conditions such as ectopic calcification and bone resorption, which may be indirectly related to
periodontal disease. Dental calculus in periodontal disease contains calcium phosphate crystals
that are deposited from excess calcium and phosphate in saliva. Alveolar bone resorption may
be linked systemically to release of parathyroid hormone in response to hypocalcemia induced
by hyperphosphatemia. More research is needed to examine the role of dysregulated phosphate
metabolism in periodontal disease.
Keywords: phosphate toxicity; periodontal disease; cancer; tumorigenesis; chronic kidney
disease-mineral and bone disorder; dental calculus; resorption; RNA; global health;
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1. Introduction
The global burden of periodontal disease, which accounts for the majority of the 442 billion USD
spent on oral disease costs, share risk factors, and social determinants with other non-communicable
diseases such as diabetes, heart disease, and cancer [1]. Recent studies investigating the link between
periodontal disease and various cancers include meta-analyses of periodontal disease and cancer [2,3],
studies of periodontal disease and cancer in postmenopausal women [4,5], in male non-smokers [6],
and studies and meta-analyses of periodontal disease linked to specific cancers including breast
cancer [7,8], pancreatic cancer [9,10], oral cancer [11,12], colorectal cancer [13,14], lymphoma [14,15],
head and neck cancer [16], lung cancer [17,18], prostate cancer [19], and gastric cancer [20]. To the
author’s knowledge, no findings from major studies published within the last five years have failed to
support an association of periodontal disease with at least some type of cancer risk. Discrepancies
between studies regarding specific cancers may be accounted for by the study design, population
studied, and method used to measure periodontal disease [5].
Despite consistent findings supporting a positive association between periodontal disease and
cancer, replete with hypotheses implicating oral microorganisms and systemic inflammation, a
common causal mechanism has not been identified in the etiology of these two non-communicable
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diseases. It is not clear if periodontal disease causes cancer, or cancer causes periodontal disease, or
some other common pathophysiological determinant causes both diseases. This perspective article
reviews evidence supporting a novel hypothesis that the association of periodontal disease with cancer
may be mediated by the pathophysiological determinant of dysregulated phosphate metabolism.
The reader should bear in mind that statements related to the proposed hypothesis in this article
are hypothetical, and further research is required for acceptance or rejection of this hypothesis.
The discovery of a common cause linking periodontal disease and cancer has possible global health
implications, suggesting a reduction in the global burden of these non-communicable diseases by
modifying their common lifestyle risk factors and determinants.
2. Phosphate Toxicity as a Global Health Burden
Phosphorus, an essential dietary micronutrient, is ingested as phosphate in food and food
additives. The highest amount of phosphate within the body is stored in bone as calcium phosphate.
Levels of serum phosphate are regulated through a hormonal network, involving the kidneys, parathyroid
glands, intestines, and the skeletal system [21]. Bioactive vitamin D, 1,25(OH)2D3, increases intestinal
absorption of dietary phosphate, mainly through enhanced expression of sodium-phosphate 2b
cotransporters. Fibroblast growth factor 23 (FGF23) is produced within osteocytes and osteoblasts
of bone. Working in conjunction with its co-factor, Klotho, FGF23 lowers serum phosphate levels, and
increases urinary phosphate excretion by suppressing reabsorption through action of sodium-phosphate
cotransporters in the kidneys. Phosphorus renal reabsorption is also decreased by parathyroid hormone
(PTH). If phosphate is dysregulated due to kidney burden and excessive dietary phosphate intake, serum
phosphate levels may rise (hyperphosphatemia) and excessive phosphate may be sequestered in cellular
tissue producing a pathological condition called phosphate toxicity.
Phosphate toxicity is emerging as a global health concern as average amounts of dietary phosphate
intake increase to approximately double the Recommended Dietary Allowance of 700 mg per day
for an adult [22]. An excessive amount of phosphate stored in the body tissue may not always
correlate with serum levels. It is possible that phosphate toxicity may be present in the body
cells even in normophosphatemia, disturbing the function of almost every system in the body,
including the muscular, skeletal, and vascular systems, and increasing morbidity and mortality [23].
Genetic evidence from animal experiments shows that phosphate toxicity may also accelerate
mammalian aging [24], and phosphate toxicity is associated with tumorigenesis [25].
3. Dysregulated Phosphate Metabolism and Cancer
Evidence supporting the role of dysregulated phosphate metabolism and phosphate toxicity
in tumorigenesis has been detailed elsewhere [26,27]; a very brief summary of that evidence
with important relevance to periodontal disease is presented here. Cancer cells express more
phosphate cotransporters within their cell membranes than normal cells [28], which allow cancer
cells to absorb and retain greater amounts of phosphate from the tumor microenvironment.
Solid tumors have filopodia and lamellipodia that extend cancer cell membranes throughout the
tumor microenvironment [29]. Phosphorus is a limiting factor in biological growth [30] and is the
least abundantly supplied element in the formation of nucleic acids DNA and RNA. The sequestration
of dysregulated amounts of phosphorus in cancer cells is associated with additional biosynthesis
of ribosomal RNA [31], which increases protein synthesis necessary for cancer cell growth and
tumorigenesis. Of relevance, detection of the overexpression of circulating microRNA fragments
associated with dysregulated RNA biogenesis has potential as a cancer biomarker [32].
While serum phosphorus levels are not always a reliable indicator of phosphate stored in the body,
a study of cancer patients found that they had abnormally higher serum phosphate levels compared to
control patients [33]. The Health Professionals Follow-Up Study found that high-grade prostate cancer
was associated with high dietary phosphate levels [34]. High dietary phosphorus fed to experimental
animals caused skin cancer [35] and lung tumors [36]. Of relevance, experimental studies showing
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causative effects of cancer from feeding the milk protein casein [37] may not have controlled for high
levels of phosphorus within casein, which is classified as a phosphoprotein [38]. Other studies have
shown that high amounts of phosphate stimulate tumor neovascularization [39] and cell signaling in
cancer growth [40], and are associated with chromosome instability [41] and metastasis [42]. Phosphate
toxicity also contributes to systemic inflammation and malnutrition [43], which is seen in terminally ill
cancer patients with cachexia.
4. Periodontal Disease
The periodontium functions to connect teeth to bone; its structures consist of the cementum,
periodontal ligament, gingiva, and alveolar bone. Periodontal disease is the most common cause of
adult tooth loss [44]. Many mediators of inflammation in periodontal disease are associated with
cancer risk, such as C-reactive protein (CRP), Matrix metalloprotenases (MMP), Tumor Necrosis
Factor (TNF), and Interluekin (IL) [45]. Inflammation within the periodontium may begin as gingivitis
and eventually progress to periodontitis, which is usually associated with the accumulation of dental
plaque or calculus. Dental calculus is formed supragingvally and subgingivally when biofilms rich in
bacteria are mineralized with various crystals of calcium phosphate, including octacalcium phosphate =
Ca4H(PO4)3 · 2H2O, brushite = CaH(PO4) · 2H2O, hydroxyapatite = Ca5(PO43(OH), and whitlockite that
contains a small amount of magnesium and other elements = β-Ca3(PO4)2 [46]. While growth of bacteria
in the oral microbiota is associated with periodontal disease, there is currently insufficient evidence to
either support or exclude a causative role of bacterial invasion in the etiology of periodontal disease [47].
As an alternative explanation for the development of periodontal disease and its association with
cancer, Figure 1 in this perspective article shows that excessive dietary phosphate and renal burden
may increase the risk for dysregulated phosphate metabolism. It is hypothesized that this systemic
metabolic pathology could mediate the association of tumorigenesis with periodontal disease through
separate causal pathways involving phosphate toxicity and systemic chronic kidney disease-mineral
and bone disorder (CKD-MBD), respectively.
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Figure 1. Evidence suggests that excessive dietary phosphate and renal burden increases the risk of
dysregulated phosphate metabolism. It is hypothesized that dysregulated phosphate metabolism could
act as a mediator or intermediary variable linking phosphate toxicity and systemic chronic kidney
disease- ineral and bone disorder (CKD-MBD). Phosphate toxicity may progress to tumorigenesis, and
period ntal disease may occur as a c morbidity with systemic CKD-MBD, which forms an association
between tumorigenesis and periodontal disease (dotted arrow).
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5. Chronic Kidney Disease-Mineral and Bone Disorder
Phosphate metabolism is often dysregulated in chronic kidney disease (CKD), and
hyperphosphatemia contributes to patient morbidity and mortality [48]. CKD is often comorbid with
cancer [49], and an association of periodontal disease with CKD has been confirmed in observational
studies [50–52]. As in cancer, it is plausible that the association of periodontal disease with CKD
also involves dysregulated phosphate and calcium metabolism, seen in systemic CKD-MBD [53].
In addition to endocrine disturbances in the metabolism of ions and hormones associated with
bone, characterization of chronic kidney disease-mineral and bone disorder (CKD-MBD) includes
abnormalities in bone mineralization, bone growth, and bone turnover. Jaw bones affected with
CKD-MBD increase the risk of bone loss in periodontitis [54].
While severity of periodontal disease was found to increase with stages of CKD, serum
albumin levels declined as periodontal disease severity increased [55]. Of relevance, increasing
hyperphosphatemia in CKD is also associated with declining serum albumin levels [56], implying that
hyperphosphatemia may also be positively associated with periodontal disease severity. It has been
observed that dental calculus formation appears to be similar to ectopic calcification such as that which
occurs in kidney stone formation [57], and an association has been found between calculus formation
and renal calculi [58]. Of relevance, ectopic calcification, including calcification of the vascular system,
is associated with dysregulated phosphate metabolism and hyperphosphatemia [27].
Hyperphosphatemia is a common condition in dialysis patients [59], and dialysis patients were
found to have a higher rate of dental calculus formation compared to healthy controls [60], further
implying a role for high serum phosphate levels in calculus formation. Calculus that formed in closer
proximity to salivary gland ducts was also found to contain more calcium and phosphate than calculus
in other oral locations [46]. Increased phosphate and calcium in saliva has been associated with higher
risk for inflammation of the periodontium [61], and high levels of phosphorus have been linked to
systemic inflammation [43], which is often present in periodontal disease and cancer. Of relevance,
detection of ribose nucleic acids in saliva is used in oral cancer diagnosis [62], and as previously
mentioned, phosphorus is a key element in the formation of nucleic acids detected in circulating
microRNA [32]. Furthermore, increased periodontal risk has been associated with carotid artery
calcifications [63] and increased aortic arch plaque thickness [64], which may be related to vascular
ectopic calcification caused by elevated serum phosphate associated with periodontal disease.
Recent studies confirm an association of systemic osteoporosis with periodontal disease [65–72].
Bone resorption related to dysregulated phosphate metabolism may be initiated when high levels of
phosphate in the serum unite with free calcium ions (Ca2+) to form excess levels of calcium phosphate,
which induces hypocalcemia. In response, parathyroid hormone secretion resorbs calcium from bone,
which immediately restores low serum levels of free calcium [73]. The paradox of normal serum calcium
levels in osteoporosis explains why osteoporosis is considered a silent disease, which is often not
diagnosed until fractures occur. According to the guidelines of KDIGO (Kidney Disease: Improving
Global Outcomes), bone turnover markers like serum levels of PTH are the preferred diagnostic
indicator for impaired bone quality, rather than invasive bone biopsies [74]. As excess levels of calcium
phosphate rise in the serum, calcium phosphate may be deposited in soft tissue forming ectopic
calcifications. Abnormal calcification may also occur in bone itself, as seen in osteoblastic metastasis
in breast, prostate, and other bone metastatic cancers [75]. Of relevance, the concurrent systemic
pathologies of osteoporosis and ectopic calcification were first described as metastatic calcification by
Virchow in 1855 [76]. While conducting autopsies, Virchow observed that calcium phosphate appeared
to flow out of the bones and metastasize to other tissue, although he did not understand the mediating
role of PTH in this pathology. A similar PTH mechanism associated with dysregulated phosphate
(as seen in secondary hyperparathyroidism) could help explain why ectopic dental calculus forms
concurrently with alveolar bone resorption and tooth loss in periodontal disease. Further research
is needed to examine the role of dysregulated phosphate metabolism and hyperphosphatemia in
periodontal disease.
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6. Conclusions
Explaining a common cause linking periodontal disease with cancer has possible global health
implications, suggesting that a reduction in the global burden of these non-communicable diseases
may be possible by modifying their common lifestyle risk factors and determinants. This perspective
article hypothesizes that the association of cancer with periodontal disease may be mediated by
the pathophysiological determinant of dysregulated phosphate metabolism related to high dietary
phosphate intake and kidney burden. Evidence supports the role of phosphate toxicity in cancer
development, and periodontal disease is an associated comorbidity with chronic kidney disease, in
which systemic CKD-mineral and bone disorder is common. More research is needed to establish the
role of dysregulated phosphate metabolism in periodontal disease.
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